Shaheenah Dawood, Ana M. Gonzalez-Angulo, Florentia Peintinger, Kristine Broglio, William F. Symmans, Shu-Wan Kau, Rabiul Islam, Gabriel N. Hortobagyi and Aman U. Buzdar Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin Cancer 110
Article first published online: 23 JUL 2007 | DOI: 10.1002/cncr.22895
The purpose of this study was to assess the efficacy and safety of a preoperative trastuzumab/anthrocycline chemotherapy regimen given outside the controlled environment of a clinical trial. Stage II and III HER2-positive breast cancer patients achieved a high rate of pathologic complete response with trastuzumab given concurrently with paclitaxel and FEC75 (fluorouracil, epirubicin, cyclophosphamide) chemotherapy. No severe cardiac events were observed with the regimen. The data concur with the results of a previously published trial.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field